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h Joint first authors.Early detection of oral squamous cell cancer (OSCC) is the key to improve the low 5-year survival rate.
Using proteomic and genomic technologies we have previously discovered and validated salivary OSCC
markers in American patients. The question arises whether these biomarkers are discriminatory in
cohorts of different ethnic background. Six transcriptome (DUSP1, IL8, IL1B, OAZ1, SAT1, and S100P)
and three proteome (IL1B, IL8, and M2BP) biomarkers were tested on 18 early and 17 late stage OSCC
patients and 51 healthy controls with quantitative PCR and ELISA. Four transcriptome (IL8, IL1B, SAT1,
and S100P) and all proteome biomarkers were significantly elevated (p < 0.05) in OSCC patients. The com-
bination of markers yielded an AUC of 0.86, 0.85 and 0.88 for OSCC total, T1–T2, and T3–T4, respectively.
The sensitivity/specificity for OSCC total was 0.89/0.78, for T1–T2 0.67/0.96, and for T3–T4 0.82/0.84. In
conclusion, seven of the nine salivary biomarkers (three proteins and four mRNAs) were validated and
performed strongest in late stage cancer. Patient-based salivary diagnostics is a highly promising
approach for OSCC detection. This study shows that previously discovered and validated salivary OSCC
biomarkers are discriminatory and reproducible in a different ethnic cohort. These findings support
the feasibility to implement multi-center, multi-ethnicity clinical trials towards the pivotal validation
of salivary biomarkers for OSCC detection.
 2010 Elsevier Ltd. All rights reserved.Introduction
Globally there are 350,000 new cases of oral cancers each year,
making it the thirteenth most common cancer in the US and the
eighth most common cancer in Serbia.1,2 Oral squamous cell can-
cer (OSCC) accounts for more than 90% of all oral cancers. Whilell rights reserved.
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(D.T. Wong).official data for Serbia is not available, in the US the 5-year sur-
vival rate remains low at 60%, which is mainly due to the fact that
most OSCC are diagnosed at a late stage.1,3–5 Although rather eas-
ily accessible compared to other cancers, the diagnosis of OSCC
can be challenging since most lesions will be small and asymp-
tomatic and are easily overlooked or misjudged. Early detection
would have a great impact on survival, mortality and morbidity
of OSCC.
One of the most easy to obtain and non-invasive sources for dis-
ease biomarkers is saliva, being a mirror of the body and having
shown high discriminatory power for pancreatic cancer,6 Sjögren’s
syndrome,7 HIV,8,9 Hepatitis (A–C),10–12 and OSCC.3,13–16
The gold standard for the diagnosis of OSCC is still a biopsy of
the suspicious lesion. Obviously, taking a biopsy is not suited for
screening purposes for early oral cancer detection due to its inva-
sive nature, high cost, and need for specially trained medical per-
sonal and equipment. We have previously shown that salivary
Table 2
Validation of saliva biomarkers in OSCC/T1–T2/T3–T4 versus healthy control subjects.
Marker performance
versus control group
p-value (OSCC total/
T1–T2/T3–T4)
Mean fold increase (OSCC
total/T1–T2/T3–T4)
Protein markers
IL1B <0.0001/0.0002/
<0.0001
3.96/3.20/4.76
IL8 <0.0001/0.004/
<0.0001
3.09/2.66/3.55
M2BP 0.03/0.008/0.49 1.89/2.20/1.56
RNA markers
IL8 0.0001/0.006/
0.0008
2.85/2.45/3.34
S100P 0.001/0.003/0.02 3.24/5.10/2.01
SAT1 0.002/0.01/0.02 2.61/2.32/2.95
OAZ1 0.11/0.30/0.14 1.28/1.29/1.27
IL1Ba 0.21/0.82/0.02 0.80/0.34/1.99
DUSP1 0.17/0.21/0.36 0.62/0.88/0.43
Note: p-values determined with Mann–Whitney test.
a For IL1B mRNA, the difference between T1–T2 and T3–T4 was significant (p-
value = 0.048) with T3–T4 mean 5.87  higher than T1–T2.
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development from normal to OSCC cells can lead to altered expres-
sion of proteins3,13,16 and mRNA15 markers in saliva. One of the
biggest challenges in the field of biomarker research is that initial
studies find excellent biomarkers while subsequent studies fail to
validate. Our aim is to evaluate if the previously reported tran-
scriptomic (IL1B, IL8, SAT1, S100P, DUSP1, and OAZ1)15 and proteo-
mic (IL1B, IL8, and M2BP)3,13,16 markers discovered and validated
in American OSCC cohorts are valid in an independent cohort of
OSCC patients from Serbia. Also, for the first time we will show
the discriminatory power of the combination of transcriptomic
and proteomic salivary biomarkers and performance in early
(T1–T2) and late (T3–T4) stages OSCC.
Patients and methods
Patient selection
OSCC patients were recruited from the Clinical Center of Serbia
and Stomatology Faculty University of Belgrade, Belgrade, Serbia.
Thirty-five patients with recently diagnosed and untreated OSCC
were included in this study (mean age 60.94 ± 12.30 years, 60%
smokers, 86% males), 18 of them with tumor stages T1–T2, 17 with
stages T3–T4, and 51 healthy control subjects (mean age 38.24 ±
12.50 years, 43% smokers, 55% males). No subject had a history of
prior cancer, diabetes, autoimmune disorder, hepatitis, or HIV
infection. The study was done according to harmonized FDA-EU
Directive. All of the subjects signed the institutional review
board-approved informed consent (IC). For detailed patient charac-
teristics see Table 1 in Supplementary Data.
Saliva collection and processing
Unstimulated saliva was collected and processed as previously
described separately for RNA6 and protein portions.3 All PCR and
ELISA assays were done at Dental Research Institute, University
of California – Los Angeles, Los Angeles.
Primer design
Nested PCR assays were designed using NCBI/Primer-BLAST
software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).
Amplicons were intron-spanning whenever possible, with lengths
of 77–132 bp for the outer and 66–92 bp for the inner products.
For full gene names, gene accession numbers, and primer
sequences see Table 4. The previously validated OSCC mRNA mar-
ker H3F3A was not used in this study due to the fact that the gene
sequence has been updated several times since our first OSCC
mRNA study.15 There is no specific primer for the recent third
H3F3A sequence update (gene accession number NM 002107.3).
Every possible primer would amplify a whole cluster of genes.
RT-PCR pre-amplification and quantitative PCR (qPCR)
The pre-amplification and qPCR were done as previously de-
scribed.17 Only samples that showed specific qPCR products for
the three saliva internal reference (SIR) genes GAPDH, ACTB, and
RPS9 were included in this study. Ct values of all target genes
(OAZ1, DUSP1, SAT1, IL1B, IL8, and S100P) were normalized to
arithmetic mean of the three SIR genes.
Immunoassays
ELISAs were done for Interleukin 1 Beta (IL1B), Interleukin 8
(IL8) (both from Thermo Fisher, Rockford, IL), and s90K/Mac-2binding protein (M2BP) (IBL, Hamburg, Germany). All samples
were measured in duplicate and calculated with the respective
standard curves.Statistical analysis
For each significant biomarker and also for biomarker combina-
tions, receiver operating characteristic curve (ROC), area under the
curve (AUC), sensitivity, and specificity were determined as previ-
ously described.6Results
All three salivary protein markers (IL8, IL1B, and M2BP) and 4 of
the 6 salivary mRNAmarkers (IL8, IL1B, SAT1, and S100P) were ele-
vated in OSCC patients and could discriminate (p < 0.05) between
cancer and control subjects as single markers (Table 2, Figs. 1
and 2). All 35 OSCC patients and all 51 control subjects showed
specific qPCR products for the three salivary internal reference
(SIR) genes. M2BP was a highly significant marker for early stage
oral cancer (T1/T2) (p = 0.008) but was not discriminatory for late
stage oral cancer (T3/T4) (p = 0.49), while IL1B mRNA behaved in
the opposite manner with p = 0.82 for T1/T2 and p = 0.02 for T3/
T4 OSCC, respectively. OAZ1 was the only marker that was not val-
idated as a single marker and did not improve performance of com-
bined markers in the Serbian cohort. Based on fold changes, IL1B
protein and IL8 protein as well as S100P mRNA were increased
the most between all OSCC patients and controls with a fold
change of 3.96, 3.09, and 3.24, respectively. Combined markers
proved to be the strongest discriminator of OSCC with an AUC of
0.86 for all cancer patients (IL1B protein + SAT1 mRNA + DUSP1
mRNA), 0.85 for T1–T2 (IL1B mRNA + SAT1 mRNA + DUSP1 mRNA),
and 0.88 for T3–T4 (IL1B protein + DUSP1 mRNA) (Fig. 1 and Table
3). The sensitivity/specificity for these groups were 0.89/0.78, 0.67/
0.96, and 0.82/0.84, respectively. No biomarker could discriminate
between male OSCC and female OSCC or smoking OSCC and non-
smoking OSCC patients (all p-values >0.05 with Mann–Whitney
test). Although DUSP1 alone was not a significant single marker,
it improved the performance for combined markers in the OSCC to-
tal group and in the T3–T4 group. In general, the stratification for
early and late stages cancer showed that the salivary biomarkers
were stronger discriminators for T3–T4 than for T1–T2 OSCC
lesions.
Figure 1 Protein markers and ROC curves. Salivary protein levels (mean and standard deviation) for IL1B (panel A), IL8 (panel B), M2BP (panel C); p-values with Mann–
Whitney U test; ‘‘"’’ indicating mean fold change between cancer and control group; panel D: ROC curve analysis for the predictive power of combined salivary biomarkers.
The final logistic model included for OSCC total three markers (IL1B protein + SAT1 mRNA + DUSP1 mRNA), for T1–T2 three markers (IL1B mRNA + IL8 mRNA + SAT1 mRNA),
and for T3–T4 two markers (IL1B protein + DUSP1 mRNA) with an AUC of 0.86, 0.85, and 0.88, respectively.
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The delayed diagnosis of OSCC at advanced stages is the main
contributing factor to the poor 5-year survival rate. Currently used
clinical strategies such as biopsy, vital tissue staining and exfolia-
tive cytology will only be applicable to small patient groups and
have clear limitations.18 The aim of using salivary biomarkers for
OSCC detection is the facilitation of diagnostics at a point where
OSCC is still small and treatment is very likely to be successful. In
order to achieve this highly desirable goal, a saliva screening meth-
od must have sufficient sensitivity and specificity, be rather inex-
pensive, non-invasive, have high-throughput, and can be used by
non-trained personnel. Using the latest advancements in technol-
ogy could help put saliva in such a clinical context. Recent studies
have shown that there is an abundance of accessible salivary
biomarkers with highly discriminatory value for various dis-
eases.3,6–13,15,16 At the same time, the development of point of care
devices such as the Oral Fluid NanoSensor Test (OFNASET) platform
will provide easy to use saliva diagnostic technology.19 In this
study, we used instant centrifugation at 4 C and adding of stabiliz-
ers followed by freezing samples at 80 C. Efforts are currently
taken to develop a more convenient saliva RNA and protein preser-vation method, ideally even at room temperature. This would ease
clinical logistics, sample preparation and transport of samples.
The results from this study show that our previously found sal-
ivary biomarkers are validatable and powerful discriminators be-
tween OSCC and controls in a Serbian cohort. This is of
importance because it demonstrates that the OSCC salivary bio-
markers are likely independent of ethnicity. The combination of
markers from the proteome and transcriptome yielded the highest
predictive power for OSCC total (IL1B protein + SAT1 mRNA + -
DUSP1 mRNA) with an AUC of 0.86, 0.89 sensitivity, and 0.78 spec-
ificity. When stratifying the OSCC patients for early and late stage
cancer, the markers perform slightly stronger for late (T3–T4) than
for early OSCC lesions (T1–T2) with an AUC of 0.88 and 0.85,
respectively. Our findings underscore the correlation between the
tested biomarkers and OSCC. The performance of the markers is
slightly below but comparable to previously found results for the
transcriptome with an AUC of 0.95 and for the proteome with an
AUC of 0.93 in US cohorts.3,15
The question might be asked why there is not a single bio-
marker powerful enough to discriminate between OSCC and con-
trols alone. Expanding the number of biomarkers takes into
account the multi-factorial and heterogenic pathogenesis of OSCC,
Figure 2 mRNA markers. Salivary mRNA values (mean and standard deviation) for IL1B mRNA (panel A), IL8 (panel B), SAT1 (panel C), OAZ1 (panel D), S100P (panel E), and
DUSP1 (panel F) normalized to SIR genes (GAPDH, ACTB, RPS9); p-values with Mann–Whitney U test; ‘‘"’’ indicating mean fold change between cancer and control group; for
IL1B mRNA, T3–T4 mean was 5.87-fold higher than T1–T2 mean.
Table 3
Receiver operator characteristic (ROC) curve analysis of OSCC-associated saliva biomarkers.
Marker performance versus control group Area under ROC curve Maximum sensitivity Maximum specificity
OSCC total T1–T2 T3–T4 OSCC total T1–T2 T3–T4 OSCC total T1–T2 T3–T4
Protein markers
IL1B 0.83 0.79 0.88 0.83 0.83 0.76 0.76 0.78 0.84
IL8 0.77 0.73 0.82 0.66 0.61 0.71 0.80 0.80 0.80
M2BP 0.64 0.71 0.56 0.37 0.83 0.29 0.90 0.59 0.92
RNA markers
IL8 0.75 0.72 0.77 0.60 0.67 0.65 0.78 0.69 0.80
S100P 0.71 0.73 0.68 0.54 0.56 0.53 0.88 0.90 0.88
SAT1 0.70 0.71 0.70 0.54 0.94 0.59 0.82 0.43 0.82
OAZ1 0.60 0.58 0.62 0.40 0.39 0.41 0.92 0.92 0.41
IL1B 0.42 0.52 0.69 0.23 0.33 0.59 0.94 0.94 0.80
DUSP1 0.41 0.40 0.43 0.14 0.11 0.29 0.98 0.98 0.92
Combination of protein and RNA markers 0.86a 0.85b 0.88c 0.89a 0.67b 0.82c 0.78a 0.96b 0.84c
a Combination of IL1B protein + SAT1 + DUSP1.
b Combination of IL1B mRNA + IL8 mRNA + SAT1.
c Combination of IL1B protein + DUSP1.
54 O. Brinkmann et al. / Oral Oncology 47 (2011) 51–55thus increasing the discriminatory power of single biomarkers to
the high performance of combined biomarkers.
Some of the OSCC markers validated are inflammatory markers
(IL1B and IL8) also found in the oral cavity in other conditions than
OSCC. Studies are currently ongoing evaluating biomarkers for
periodontitis, which is the strongest and most common inflamma-
tory oral disease. A previous OSCC study already found a significant
difference for salivary IL8 protein levels between OSCC and peri-
odontitis patients.16 Our data shows that the panel of various sal-
ivary markers is truly discriminatory for OSCC.
Determining the source of OSCC related salivary biomarkers re-
mains to be a challenging field. Exfoliate cancer cells, oral mucosacells, alterations in the salivary gland secretion patterns (parotid,
submandibular, sublingual as well as minor glands) or gingival cre-
vice fluid could contribute to the saliva biomarker profile. Although
the further stratification of biomarker sources remains an impor-
tant scientific venue, only the focus on an efficacious screening
method using easy to obtain whole saliva will allow wide spread
clinical implementation.
While the results are promising and underline the power of the
salivary transcriptome and proteome markers, further studies will
be needed with larger patient numbers to allow a population-level
clinical application. A nationwide OSCC saliva biomarker validation
study is currently ongoing in a prospective-specimen collection,
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O. Brinkmann et al. / Oral Oncology 47 (2011) 51–55 55retrospective-blinded-evaluation (PRoBE) design manner20 to meet
the guidelines of the early detection network (EDRN) of the Na-
tional Cancer Institute.21
Conflict of interest statement
David T. Wong is co-founder of RNAmeTRIX Inc., a molecular
diagnostic company.
Acknowledgements
The work was supported by grant R01 DE017170 from the Na-
tional Institute of Dental Research/National Institute of Health.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.oraloncology.2010.10.009.
References
1. Cancer facts and figures 2009. Atlanta: American Cancer Society; 2009.
2. Cancer Incidence and Mortality in Central Serbia 2006, Report No. 8. Belgrade,
Serbia: Institute of Public Health of Serbia ‘‘Dr. Milan Jovanovic´ – Batut’’, Center
for Prevention and Control of Noncommunicable Diseases, Department for
Prevention and Control of Noncommunicable Diseases; 2009.
3. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary
proteomics for oral cancer biomarker discovery. Clin Cancer Res
2008;14(19):6246–52.
4. Brinkman BM, Wong DT. Disease mechanism and biomarkers of oral squamous
cell carcinoma. Curr Opin Oncol 2006;18(3):228–33.
5. Walker DM, Boey G, McDonald LA. The pathology of oral cancer. Pathology
2003;35(5):376–83.
6. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, et al. Salivary
transcriptomic biomarkers for detection of resectable pancreatic cancer.
Gastroenterology 2010;138(3):949–57. e1–7.
7. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, et al. Salivary proteomic and genomic
biomarkers for primary Sjogren’s syndrome. Arthritis Rheum
2007;56(11):3588–600.
8. Emmons W. Accuracy of oral specimen testing for human immunodeficiency
virus. Am J Med 1997;102(4A):15–20.
9. Malamud D. Oral diagnostic testing for detecting human immunodeficiency
virus-1 antibodies: a technology whose time has come. Am J Med
1997;102(4A):9–14.
10. Ochnio JJ, Scheifele DW, Ho M, Mitchell LA. New, ultrasensitive enzyme
immunoassay for detecting vaccine- and disease-induced hepatitis A virus-
specific immunoglobulin G in saliva. J Clin Microbiol 1997;35(1):98–101.
11. Chaita TM, Graham SM, Maxwell SM, Sirivasin W, Sabchareon A, Beeching NJ.
Salivary sampling for hepatitis B surface antigen carriage: a sensitive technique
suitable for epidemiological studies. Ann Trop Paediatr 1995;15(2):135–9.
12. El-Medany OM, El-Din Abdel Wahab KS, Abu Shady EA, Gad El-Hak N. Chronic
liver disease and hepatitis C virus in Egyptian patients. Hepatogastroenterology
1999;46(27):1895–903.
13. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6
and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal
squamous cell carcinoma. Arch Otolaryngol Head Neck Surg
2004;130(8):929–35.
14. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al.
Salivary microRNA: discovery, characterization, and clinical utility for oral
cancer detection. Clin Cancer Res 2009;15(17):5473–7.
15. Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, et al. Salivary transcriptome
diagnostics for oral cancer detection. Clin Cancer Res 2004;10(24):8442–50.
16. Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, et al. Multiplexed
immunobead-based assay for detection of oral cancer protein biomarkers in
saliva. Oral Dis 2008;14(8):705–12.
17. Hu Z, Zimmermann BG, Zhou H, Wang J, Henson BS, Yu W, et al. Exon-level
expression profiling: a comprehensive transcriptome analysis of oral fluids. Clin
Chem 2008;54(5):824–32.
18. Epstein JB, Zhang L, Rosin M. Advances in the diagnosis of oral premalignant
and malignant lesions. J Can Dent Assoc 2002;68(10):617–21.
19. Gau V, Wong D. Oral fluid nanosensor test (OFNASET) with advanced
electrochemical-based molecular analysis platform. Ann N Y Acad Sci
2007;1098:401–10.
20. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the
accuracy of a biomarker used for classification or prediction: standards for
study design. J Natl Cancer Inst 2008;100(20):1432–8.
21. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases
of biomarker development for early detection of cancer. J Natl Cancer Inst
2001;93(14):1054–61.
